Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of DNP007 in Healthy Subjects
NCT06400771Phase 1Recruiting
- Sponsor
- Seoul National University Hospital
- Start
- Jun 2024
- Primary completion
- Dec 2024
- Modality
- Antibody Conjugates, scFv Fragments, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of DNP007 in Liver transplant rejection (4 arms), sponsored by Seoul National University Hospital. Primary endpoints: Maximum Plasma Concentration at 672 hours, Area Under the Curve to Last Quantifiable Time Point at 672 hours and 6 more. Started Jun 2024; status: recruiting.
02
Drugs
DNP007
03
Conditions
Liver transplant rejection
Beyond the preview
Go deeper on NCT06400771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06400771.